MetaCap

AEON Biopharma (AEON) vs BioVie (BIVI)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

BioVie (BIVI) has outperformed AEON Biopharma (AEON) over the past year, losing 38.2% versus a loss of 85.2%. AEON Biopharma is the larger company by market cap ($10.3 million vs $8.6 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AEON-85.18%BIVI-38.22%
+84%-5%-94%
Nov 21, 20251 yearNov 20, 2026
AEON-99.98%BIVI-99.87%
+72%-18%-108%
Jan 2, 20235 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AEON versus BIVI key metrics
MetricAEONBIVI
Share price$0.123$0.80
Market cap$10.35M$8.58M
1-day change-7.59%-12.07%
YTD return-88.82%-31.03%
1-year return-85.18%-38.22%
5-year return—-99.87%
EPS (TTM)$-3.89$-2.85
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-39.22M$-22.07M
52-week high$1.45$3.79
52-week low$0.106$0.7515
Distance from 52-week high-91.52%-78.89%
Analyst consensusstrong_buynone
Avg. price target upside+1379.67%+557.50%
Average volume7.44M568.61K
Shares outstanding84.12M10.72M
Employees813
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • BIVI has outperformed AEON by 47.0 percentage points over the past year.

About AEON Biopharma

AEON stock →

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine.

Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees

About BioVie

BIVI stock →

BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 3 for the treatment of life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism.

Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees

AEON vs BIVI FAQ

Which is bigger, AEON Biopharma or BioVie?

AEON Biopharma (AEON) is larger, with a market capitalization of $10.35M compared with $8.58M for BioVie (BIVI).

Which stock has performed better over the past year, AEON or BIVI?

BIVI returned -38.22% over the past 12 months, compared with -85.18% for AEON (price return, excluding dividends). Past performance does not predict future results.

Are AEON Biopharma and BioVie in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons